Physician profile
Jonathan C Lockhart
NPI 1679678403
$764,569.43
in general payments reported to CMS, 2019-2025
34 companies · $107K in 2025
The $107K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $97K · 2021: $86K · 2022: $118K · 2023: $137K · 2024: $110K · 2025: $107K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $322K · Travel and Lodging: $19K · Food and Beverage: $12K · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $321,785.00 |
| Travel and Lodging | $18,964.40 |
| Food and Beverage | $12,207.12 |
| Education | $334.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $506,645.31 | 2021-2025 | |
| Allergan, INC. | $202,932.69 | 2019-2021 | |
| Eisai INC. | $27,290.54 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $9,928.74 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,083.51 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $3,032.23 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $2,261.30 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $1,057.58 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $1,022.65 | 2020-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $1,001.06 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $752.14 | 2020-2025 | Caplyta |
| Lundbeck LLC | $669.88 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $524.91 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $437.11 | 2019-2025 | Ingrezza |
| Harmony Biosciences LLC | $375.21 | 2023-2025 | Wakix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $330.01 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.80 | 2019-2022 | |
| Corium, LLC | $130.57 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $126.87 | 2020-2022 | |
| Noven Therapeutics, LLC | $106.95 | 2023-2025 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $94.25 | 2023-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $76.69 | 2021-2024 | Qelbree |
| Bausch Health US, LLC | $69.50 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $45.08 | 2019-2022 | |
| Owp Pharmaceuticals, INC. | $35.06 | 2025 | Subvenite |
| Collegium Pharmaceutical, INC. | $34.47 | 2025 | Jornay Pm |
| Tris Pharma INC | $33.98 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $29.52 | 2019-2020 | |
| Indivior INC. | $29.25 | 2023 | Perseris |
| Noven Pharmaceuticals, INC. | $22.88 | 2024 | Xelstrym |
| Genentech USA, INC. | $20.66 | 2024 | Columvi, Polivy, Lunsumio |
| Livanova USA, INC. | $20.20 | 2020 | |
| Shire North American Group INC | $13.64 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lockhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.